NZ532065A - Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure - Google Patents
Use of norepinephrine reuptake inhibitors for the treatment of cognitive failureInfo
- Publication number
- NZ532065A NZ532065A NZ532065A NZ53206502A NZ532065A NZ 532065 A NZ532065 A NZ 532065A NZ 532065 A NZ532065 A NZ 532065A NZ 53206502 A NZ53206502 A NZ 53206502A NZ 532065 A NZ532065 A NZ 532065A
- Authority
- NZ
- New Zealand
- Prior art keywords
- dementia
- use according
- atomoxetine
- disease
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33917401P | 2001-12-11 | 2001-12-11 | |
| PCT/US2002/036132 WO2003049724A1 (en) | 2001-12-11 | 2002-11-27 | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ532065A true NZ532065A (en) | 2007-03-30 |
Family
ID=23327833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ532065A NZ532065A (en) | 2001-12-11 | 2002-11-27 | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure |
Country Status (26)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05001705A (es) * | 2002-08-14 | 2005-04-19 | Pharmacia & Upjohn Co Llc | Uso de reboxetina para el tratamiento de sofocos. |
| WO2005011583A2 (en) * | 2003-07-28 | 2005-02-10 | Leslie Joe Dunaway | Treatment of allergic rhinitis and asthma |
| US20070105960A1 (en) * | 2003-08-27 | 2007-05-10 | Eli Lilly And Company | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors |
| KR20060121178A (ko) * | 2003-12-12 | 2006-11-28 | 일라이 릴리 앤드 캄파니 | 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제 |
| AP2006003771A0 (en) * | 2004-04-30 | 2006-10-31 | Warner Lambert Co | Substituted morpholine compounds for the treatmentof central nervous system disorders |
| US7439399B2 (en) * | 2004-06-28 | 2008-10-21 | Teva Pharmaceutical Fine Chemicals | Processes for the preparation of atomoxetine hydrochloride |
| US8580776B2 (en) * | 2007-07-10 | 2013-11-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating neurodegenerating diseases |
| US20100069389A1 (en) * | 2008-09-06 | 2010-03-18 | Bionevia Pharmaceuticals, Inc. | Novel forms of reboxetine |
| US20100317730A1 (en) * | 2009-06-12 | 2010-12-16 | Shaya Elias K | Treatment for menopausal and perimenopausal vasomotor symptons |
| TW201107485A (en) * | 2009-07-31 | 2011-03-01 | Univ Nat Taiwan | Treating negative symptoms of schizophrenia associated with defective neuregulin 1 (NRG1) |
| US20140249180A1 (en) * | 2011-10-03 | 2014-09-04 | National Center For Geriatrics And Gerontology | Tau aggregation inhibitor |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP2962687B1 (en) | 2013-04-02 | 2019-06-05 | The Doshisha | Tau aggregation inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| US5281624A (en) * | 1991-09-27 | 1994-01-25 | Eli Lilly And Company | N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof |
| US5658590A (en) * | 1995-01-11 | 1997-08-19 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| ATE305788T1 (de) * | 1999-07-01 | 2005-10-15 | Pharmacia & Upjohn Co Llc | (s,s)-reboxetin zur behandlung von inkontinenz |
| SK4732002A3 (en) * | 1999-10-13 | 2002-12-03 | Pfizer Prod Inc | Biaryl ether derivatives useful as monoamine reuptake inhibitors |
| WO2002053104A2 (en) * | 2001-01-02 | 2002-07-11 | Sention, Inc. | Use of catecholamine reuptake inhibitors to enhance memory |
| MXPA03006003A (es) * | 2001-01-02 | 2005-09-08 | Upjohn Co | Nuevas combinaciones de farmacos. |
-
2002
- 2002-11-27 JP JP2003550773A patent/JP2005517647A/ja active Pending
- 2002-11-27 US US10/496,765 patent/US20050009925A1/en not_active Abandoned
- 2002-11-27 KR KR10-2004-7009039A patent/KR20040066895A/ko not_active Withdrawn
- 2002-11-27 EP EP02789574A patent/EP1458368B1/en not_active Expired - Lifetime
- 2002-11-27 BR BR0213581-7A patent/BR0213581A/pt not_active IP Right Cessation
- 2002-11-27 HR HR20040528A patent/HRPK20040528B3/xx not_active IP Right Cessation
- 2002-11-27 AU AU2002352625A patent/AU2002352625A1/en not_active Abandoned
- 2002-11-27 DE DE60223718T patent/DE60223718T2/de not_active Expired - Fee Related
- 2002-11-27 ES ES02789574T patent/ES2295435T3/es not_active Expired - Lifetime
- 2002-11-27 CA CA002467802A patent/CA2467802A1/en not_active Abandoned
- 2002-11-27 SK SK244-2004A patent/SK2442004A3/sk not_active Application Discontinuation
- 2002-11-27 MX MXPA04005716A patent/MXPA04005716A/es not_active Application Discontinuation
- 2002-11-27 NZ NZ532065A patent/NZ532065A/en unknown
- 2002-11-27 HU HU0402619A patent/HUP0402619A3/hu unknown
- 2002-11-27 PL PL02369311A patent/PL369311A1/xx unknown
- 2002-11-27 WO PCT/US2002/036132 patent/WO2003049724A1/en not_active Ceased
- 2002-11-27 CZ CZ2004709A patent/CZ2004709A3/cs unknown
- 2002-11-27 IL IL16198902A patent/IL161989A0/xx unknown
- 2002-11-27 EA EA200400793A patent/EA200400793A1/ru unknown
- 2002-11-27 CN CNA028247264A patent/CN1713900A/zh active Pending
- 2002-12-05 MY MYPI20024591A patent/MY136367A/en unknown
- 2002-12-05 TW TW091135296A patent/TW200300672A/zh unknown
-
2004
- 2004-05-31 ZA ZA200404274A patent/ZA200404274B/en unknown
- 2004-06-09 EC EC2004005145A patent/ECSP045145A/es unknown
- 2004-06-09 CO CO04054292A patent/CO5590907A2/es not_active Application Discontinuation
- 2004-07-09 NO NO20042904A patent/NO20042904L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL369311A1 (en) | 2005-04-18 |
| NO20042904L (no) | 2004-09-07 |
| JP2005517647A (ja) | 2005-06-16 |
| AU2002352625A1 (en) | 2003-06-23 |
| ES2295435T3 (es) | 2008-04-16 |
| SK2442004A3 (en) | 2004-12-01 |
| MY136367A (en) | 2008-09-30 |
| MXPA04005716A (es) | 2004-12-06 |
| CN1713900A (zh) | 2005-12-28 |
| HUP0402619A3 (en) | 2008-04-28 |
| BR0213581A (pt) | 2004-08-24 |
| CZ2004709A3 (cs) | 2004-10-13 |
| HUP0402619A2 (hu) | 2005-03-29 |
| EP1458368B1 (en) | 2007-11-21 |
| EP1458368A1 (en) | 2004-09-22 |
| ZA200404274B (en) | 2005-09-13 |
| HRPK20040528B3 (en) | 2006-03-31 |
| US20050009925A1 (en) | 2005-01-13 |
| DE60223718D1 (de) | 2008-01-03 |
| DE60223718T2 (de) | 2008-10-30 |
| CO5590907A2 (es) | 2005-12-30 |
| KR20040066895A (ko) | 2004-07-27 |
| WO2003049724A1 (en) | 2003-06-19 |
| CA2467802A1 (en) | 2003-06-19 |
| EA200400793A1 (ru) | 2004-10-28 |
| TW200300672A (en) | 2003-06-16 |
| ECSP045145A (es) | 2004-07-23 |
| HRP20040528A2 (en) | 2004-10-31 |
| IL161989A0 (en) | 2005-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006515628A (ja) | ヒト神経精神疾患を処置するためのn−デスメチルクロザピンの使用 | |
| EP1238676B1 (en) | Combination of a serotonin reuptake inhibitor and an atypical antipsychotic for use in depression, obsessive compulsive disorder and psychosis | |
| CA2332814C (en) | Combination therapy for treatment of refractory depression | |
| US20050009925A1 (en) | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure | |
| CA2525366A1 (en) | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines | |
| US6960577B2 (en) | Combination therapy for treatment of refractory depression | |
| US20090258084A1 (en) | Mono and Combination Therapy with a M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Cognitive Disorders in Schizophrenia | |
| US20070015763A1 (en) | Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist | |
| US7884096B2 (en) | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | |
| US20080200555A1 (en) | Use of norepinephrine reuptake inhibitors for the treatment of tic disorders | |
| JP2022511266A (ja) | 陰性症状および障害を処置するため、神経可塑性を増大するため、ならびに神経保護を促進するためのロルペリドンの使用 | |
| CZ20031339A3 (cs) | Léčení úzkostných poruch | |
| SK14502000A3 (sk) | Kombinácie liekov n. a. r. i. (inhibítorov reaktivácie noradrenalínu), výhodne reboxetínu, a pindololu | |
| RU2508106C2 (ru) | Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии | |
| RU2238084C2 (ru) | Композиции, содержащие ингибиторы обратного захвата допамина, и способы их применения | |
| JP7556031B2 (ja) | 認知症患者の行動心理学的症状の治療 | |
| EP4537826A1 (en) | Method for treating mental diseases | |
| RU2508096C2 (ru) | Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии | |
| HK40071665B (en) | Treating behavioral and psychological symptoms in dementia patients | |
| TW202132278A (zh) | 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途 | |
| MXPA00011353A (es) | Uso de olanzapida en combinación con fluoxetina para terapia de la depresión refractaria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed |